All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Not reported | 2016-001033-27 | REMODEL - WM3 An Open Label non-randomized Phase II Study exploring «chemo-free » treatment association with Idelalisib + Obinutuzumab in Patient with relapsed/refractory Waldenstrom’s Macroglobulinem... | 2023-04-13 | due-trials |
Other | 2018-001475-20 | Preemptive therapy with Venetoclax for high risk CLL stage A patients, a phase II trial of the FILO PREVENE (PREemptive Venetoclax) trial | not-yet-due | |
Completed, but no date | 2018-003483-32 | BLINAtumomab after R-CHOP debulking therapy for patients with Richter Transformation. | bad-data | |
Other | 2020-005866-32 | A phase II randomized study to assess the efficacy on outcome of Venetoclax combined with Cytarabine versus Idarubicin combined with Cytarabine administered as post-remission therapy to elderly patien... | not-yet-due | |
Other | 2020-006081-36 | STop and restart Acalabrutinib In fRail patients with previously untreated CLL (STAIR) Arrêt et reprise de l’Acalabrutinib chez les patients fragiles présentant une leucémie lymphoîde chronique no... | not-yet-due | |
Completed, but no date | 2021-002042-32 | A phase II study of CPX-351 monotherapy in Acute Myeloid Leukemia secondary to Myeloproliferative neoplams Étude de phase ii d’une monothérapie par cpx-351 dans les leucémies aiguës secondaires à ... | bad-data |